Developer docs
API playgroundTry for free, no card

Search company profiles

Shockwave Medical

Full company profile

uuid0004zqv

Namestring
Shockwave Medical
Legal namestring
Shockwave Medical, Inc.
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Shockwave Medical is a medical device company that develops and commercializes Intravascular Lithotripsy (IVL), a catheter-based technology that uses ultrasonic acoustic pressure waves to modify calcified plaque in coronary and peripheral arteries, enabling safer and more effective deployment of balloon catheters and stents in severely hardened vessels. The product portfolio spans coronary IVL catheters (C2, C2+, C2 Aero, C2 Aero Fly), peripheral IVL catheters (E8, Javelin, L6, M5, M5+, S4), supporting generators and connector cables, the investigational Shockwave Reducer coronary sinus reduction device for refractory angina, and the investigational SkyRunner Carotid IVL System. The technology is supported by an extensive clinical evidence program including the DISRUPT CAD I-IV, DISRUPT PAD III, and DISRUPT BTK studies, with additional trials in refractory angina (COSIRA II), carotid disease (SKYWARD IDE), and female-specific outcomes (EMPOWER CAD).

The company sells its devices primarily through direct enterprise field sales to hospitals and cardiac centers serving interventional cardiologists, interventional radiologists, and vascular surgeons in the United States, Europe, and Japan. Pricing is negotiated directly with healthcare institutions and is not publicly disclosed; revenue is generated through hardware sales of catheters and capital equipment. Shockwave Medical was founded in 2009 and is headquartered in Santa Clara, California. In May 2024, Johnson & Johnson completed its acquisition of Shockwave Medical for approximately $13.1 billion, making it a wholly-owned subsidiary within J&J MedTech. Following the acquisition, Shockwave surpassed $1 billion in annual sales with 23% growth in 2025, establishing itself as a blockbuster cardiovascular platform within the J&J portfolio. In May 2026, Rubicon Point Partners acquired the Santa Clara headquarters campus, which remains fully leased to Shockwave under a triple-net arrangement.

Short descriptiontext

Shockwave Medical develops and sells Intravascular Lithotripsy (IVL) catheters and generators that use ultrasonic pressure waves to treat calcified coronary and peripheral artery disease, serving interventional cardiologists, vascular surgeons, and hospitals globally. A wholly-owned J&J MedTech subsidiary since May 2024.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersFremont, United States
HQ citystring
Fremont
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intravascular lithotripsy devices, coronary artery disease treatment, peripheral artery disease treatment, calcified plaque modification, cardiovascular medical devices
Industry2 codes
1Interventional Cardiology (PCI/Structural Heart)
CodeHLAKABABPrimaryYes
2Thrombectomy, Embolic Protection & Stroke Intervention Devices
CodeHLAHAFAJPrimaryNo
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Intravascular Lithotripsy (IVL) Cardiovascular Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Shockwave Medical generates revenue through the sale of its intravascular lithotripsy (IVL) devices and generators to hospitals and healthcare providers. The company reported preliminary FY 2022 revenues of around $490 million and projected FY 2023 revenues of $660-$680 million. Post-acquisition by J&J, the business surpassed $1 billion in annual sales.

shockwavemedical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Shockwave IVL (Intravascular Lithotripsy)
Description

The company's core technology platform using ultrasonic acoustic pressure waves to modify calcified plaque in coronary and peripheral arteries

shockwavemedical.com:443
+6 more records
Core offering1 text field

Shockwave Medical develops, manufactures, and commercializes Intravascular Lithotripsy (IVL) devices — including coronary and peripheral IVL catheters, an IVL generator, connector cable, and investigational Reducer and SkyRunner systems — that use ultrasonic acoustic pressure waves to safely modify calcified plaque in cardiovascular arteries. These products are sold to hospitals, cardiac catheterization labs, and interventional specialists for the treatment of severely calcified coronary and peripheral artery disease, as well as refractory angina (under investigation in the US).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 23% growth post-acquisition by J&J
+3 more records
Product overview1 text field

Shockwave Medical pioneered the Shockwave Intravascular Lithotripsy (IVL) system, a transformative platform technology that uses ultrasonic acoustic pressure waves to safely modify calcified plaque in cardiovascular arteries. The product portfolio centers on two main device categories: Coronary IVL (Shockwave C2, C2+, C2 Aero, C2 Aero Fly) and Peripheral IVL (Shockwave E8, Javelin, L6, M5, M5+, S4), supported by the IVL Generator and Connector Cable. The system enables balloon catheters and stents to work effectively in severely hardened arteries where traditional interventions posed high risks. Additionally, the company is developing the Shockwave Reducer (investigational in US/Canada) for refractory angina treatment. Shockwave Medical operates as a wholly owned subsidiary of Johnson & Johnson MedTech following the $13.1 billion acquisition completed in May 2024.

Product and service14 records
1Shockwave C2 Coronary IVL Catheter
CategoryCoronary IVL Catheter
Description

Coronary intravascular lithotripsy catheter designed to modify calcified plaque in coronary arteries using ultrasonic acoustic pressure waves, enabling effective balloon and stent deployment in severely calcified lesions. For use by interventional cardiologists in hospital catheterization labs.

2Shockwave C2+ Coronary IVL Catheter
CategoryCoronary IVL Catheter
Description

Enhanced coronary IVL catheter with improved deliverability for treating calcified coronary artery disease.

3Shockwave C2 Aero Coronary IVL Catheter
CategoryCoronary IVL Catheter
Description

Next-generation coronary IVL catheter featuring enhanced deliverability through tortuous arteries, tapered tip design, hydrophilic coating for improved lesion crossing, and bidirectional repositioning capabilities. Available in the United States and Japan with rollout to Europe and Canada following.

4Shockwave C2 Aero Fly Coronary IVL Catheter
CategoryCoronary IVL Catheter
Description

Coronary IVL catheter variant with fly design characteristics for enhanced procedural navigation during PCI in calcified coronary arteries.

5Shockwave E8 Peripheral IVL Catheter
CategoryPeripheral IVL Catheter
Description

Peripheral intravascular lithotripsy catheter designed for treatment of calcified peripheral artery disease, particularly in larger vessel diameters.

6Shockwave Javelin Peripheral IVL Catheter
CategoryPeripheral IVL Catheter
Description

Peripheral IVL catheter designed to treat difficult-to-cross calcified lesions in peripheral arteries, featuring an enhanced crossing profile for challenging peripheral anatomy.

7Shockwave L6 Peripheral IVL Catheter
CategoryPeripheral IVL Catheter
Description

Peripheral IVL catheter for treating calcified lesions in larger peripheral vessels.

8Shockwave M5 Peripheral IVL Catheter
CategoryPeripheral IVL Catheter
Description

Peripheral IVL catheter system for treating calcified peripheral artery disease.

9Shockwave M5+ Peripheral IVL Catheter
CategoryPeripheral IVL Catheter
Description

Enhanced version of the Shockwave M5 peripheral IVL catheter for treating calcified peripheral artery disease.

10Shockwave S4 Peripheral IVL Catheter
CategoryPeripheral IVL Catheter
Description

Peripheral IVL catheter for treating calcified lesions in smaller peripheral vessels.

11Shockwave IVL Generator
CategoryIVL Device Component / Capital Equipment
Description

Generator system that powers Shockwave IVL catheters by delivering the electrical signals that produce ultrasonic acoustic pressure waves for calcium modification in coronary and peripheral arteries. Sold to hospitals as part of the IVL capital equipment footprint.

12IVL Connector Cable
CategoryIVL Device Component / Accessory
Description

Connecting cable that links the Shockwave IVL generator to the IVL catheter for energy delivery during procedures.

13Shockwave Reducer (Rejuvenator System)
CategoryCoronary Sinus Reduction Device
Description

Coronary sinus reduction device designed to treat refractory angina by reducing pressure in the coronary sinus. Investigational in the United States and Canada; available in select international geographies. For use by interventional cardiologists treating patients with chronic refractory angina.

14Shockwave SkyRunner Carotid IVL System
CategoryCarotid IVL Device (Investigational)
Description

Investigational carotid intravascular lithotripsy system designed to treat calcified carotid arteries prior to stenting. Features rapid exchange capability and tailored sizing for carotid procedures. Currently in the SKYWARD IDE clinical program enrolling up to 320 subjects across 50 US sites.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-04-11
Description

Shockwave Medical completed acquisition of Neovasc Inc. for approximately $100 million, including the Rejuvenator/Reducer System designed to treat refractory angina. The deal involved cash payment and potential deferred payments based on regulatory milestones, with Neovasc's shares being delisted from stock exchanges.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major cardiovascular device incumbent; acquired Bolt Medical to enter the IVL category, directly challenging Shockwave's coronary and peripheral IVL franchises with a much larger commercial footprint.

TypeRegional player
Description

Peripheral vascular and thrombectomy device company with overlapping peripheral intervention customer base, particularly in hospital and outpatient settings.

TypeDirect peer
Description

Specialist in peripheral vascular and thrombectomy interventions, with a growing footprint in treating complex PAD — overlapping with Shockwave's peripheral IVL and below-the-knee indications.

TypeBroad incumbent
Description

Large incumbent in coronary and peripheral intervention; acquired Cardiovascular Systems Inc. (CSI) to add orbital atherectomy for calcium modification, a directly competing calcium-treatment modality.

TypeDirect peer
Description

Focused on carotid artery stenting (TCAR); directly comparable to Shockwave's emerging SkyRunner Carotid IVL program as the carotid indication expands.

TypeEmerging player
Description

Developer of ultrasound-based renal denervation therapy; shares Shockwave's use of acoustic energy in vascular applications, making it thematically comparable in modality, if not in indication.

TypeDirect peer
Description

Pioneer of orbital atherectomy for treating calcified coronary and peripheral lesions; now part of Abbott, it is the most direct mechanistic competitor to Shockwave IVL in calcium modification.

TypeEmerging player
Description

Developer of specialty peripheral vascular devices including dedicated tools for calcified lesions; a smaller, emerging competitor with overlapping peripheral IVL-adjacent use cases.

TypeEmerging player
Description

Focused on below-the-knee and chronic limb-threatening ischemia interventions, directly adjacent to Shockwave's DISRUPT BTK clinical program and peripheral IVL use cases.

TypeBroad incumbent
Description

Global medtech incumbent with significant coronary and peripheral vascular device franchises; offers atherectomy, specialty balloons, and stents that overlap with Shockwave's procedural adjacency.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Shockwave Medical

Intravascular Lithotripsy (IVL) Cardiovascular Devicesshockwavemedical.com

Shockwave Medical develops and sells Intravascular Lithotripsy (IVL) catheters and generators that use ultrasonic pressure waves to treat calcified coronary and peripheral artery disease, serving interventional cardiologists, vascular surgeons, and hospitals globally. A wholly-owned J&J MedTech subsidiary since May 2024.

What Shockwave Medical does

Shockwave Medical is a medical device company that develops and commercializes Intravascular Lithotripsy (IVL), a catheter-based technology that uses ultrasonic acoustic pressure waves to modify calcified plaque in coronary and peripheral arteries, enabling safer and more effective deployment of balloon catheters and stents in severely hardened vessels. The product portfolio spans coronary IVL catheters (C2, C2+, C2 Aero, C2 Aero Fly), peripheral IVL catheters (E8, Javelin, L6, M5, M5+, S4), supporting generators and connector cables, the investigational Shockwave Reducer coronary sinus reduction device for refractory angina, and the investigational SkyRunner Carotid IVL System. The technology is supported by an extensive clinical evidence program including the DISRUPT CAD I-IV, DISRUPT PAD III, and DISRUPT BTK studies, with additional trials in refractory angina (COSIRA II), carotid disease (SKYWARD IDE), and female-specific outcomes (EMPOWER CAD).

The company sells its devices primarily through direct enterprise field sales to hospitals and cardiac centers serving interventional cardiologists, interventional radiologists, and vascular surgeons in the United States, Europe, and Japan. Pricing is negotiated directly with healthcare institutions and is not publicly disclosed; revenue is generated through hardware sales of catheters and capital equipment. Shockwave Medical was founded in 2009 and is headquartered in Santa Clara, California. In May 2024, Johnson & Johnson completed its acquisition of Shockwave Medical for approximately $13.1 billion, making it a wholly-owned subsidiary within J&J MedTech. Following the acquisition, Shockwave surpassed $1 billion in annual sales with 23% growth in 2025, establishing itself as a blockbuster cardiovascular platform within the J&J portfolio. In May 2026, Rubicon Point Partners acquired the Santa Clara headquarters campus, which remains fully leased to Shockwave under a triple-net arrangement.

Shockwave Medical firmographics

Firmographics
Name
Shockwave Medical
Legal name
Shockwave Medical, Inc.
Website
https://shockwavemedical.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Shockwave Medical develops and sells Intravascular Lithotripsy (IVL) catheters and generators that use ultrasonic pressure waves to treat calcified coronary and peripheral artery disease, serving interventional cardiologists, vascular surgeons, and hospitals globally. A wholly-owned J&J MedTech subsidiary since May 2024.
Ownership category
akta.pro rank

Shockwave Medical industry classification

Industry
Product category
Intravascular Lithotripsy (IVL) Cardiovascular Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro primary industry
Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)
akta.pro secondary industry
Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

  • Intravascular lithotripsy devices
  • Coronary artery disease treatment
  • Peripheral artery disease treatment
  • Calcified plaque modification
  • Cardiovascular medical devices

Where Shockwave Medical is headquartered

Location

Headquarters

HQ city
Fremont
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Shockwave Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Medical Device Sales: Shockwave Medical generates revenue through the sale of its intravascular lithotripsy (IVL) devices and generators to hospitals and healthcare providers. The company reported preliminary FY 2022 revenues of around $490 million and projected FY 2023 revenues of $660-$680 million. Post-acquisition by J&J, the business surpassed $1 billion in annual sales.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Shockwave Medical product offering

Product offering

Core offering

Shockwave Medical develops, manufactures, and commercializes Intravascular Lithotripsy (IVL) devices — including coronary and peripheral IVL catheters, an IVL generator, connector cable, and investigational Reducer and SkyRunner systems — that use ultrasonic acoustic pressure waves to safely modify calcified plaque in cardiovascular arteries. These products are sold to hospitals, cardiac catheterization labs, and interventional specialists for the treatment of severely calcified coronary and peripheral artery disease, as well as refractory angina (under investigation in the US).

Product overview

Shockwave Medical pioneered the Shockwave Intravascular Lithotripsy (IVL) system, a transformative platform technology that uses ultrasonic acoustic pressure waves to safely modify calcified plaque in cardiovascular arteries. The product portfolio centers on two main device categories: Coronary IVL (Shockwave C2, C2+, C2 Aero, C2 Aero Fly) and Peripheral IVL (Shockwave E8, Javelin, L6, M5, M5+, S4), supported by the IVL Generator and Connector Cable. The system enables balloon catheters and stents to work effectively in severely hardened arteries where traditional interventions posed high risks. Additionally, the company is developing the Shockwave Reducer (investigational in US/Canada) for refractory angina treatment. Shockwave Medical operates as a wholly owned subsidiary of Johnson & Johnson MedTech following the $13.1 billion acquisition completed in May 2024.

Differentiator

Problem solved

Functional benefit

Brands

  • Shockwave IVL (Intravascular Lithotripsy): The company's core technology platform using ultrasonic acoustic pressure waves to modify calcified plaque in coronary and peripheral arteries
  • Shockwave C2
  • Shockwave C2 Aero
  • Shockwave E8
  • Shockwave Javelin
  • Shockwave SkyRunner Carotid IVL System
  • Shockwave Reducer

Products and services

  • Shockwave C2 Coronary IVL Catheter Coronary intravascular lithotripsy catheter designed to modify calcified plaque in coronary arteries using ultrasonic acoustic pressure waves, enabling effective balloon and stent deployment in severely calcified lesions. For use by interventional cardiologists in hospital catheterization labs.
  • Shockwave C2+ Coronary IVL Catheter Enhanced coronary IVL catheter with improved deliverability for treating calcified coronary artery disease.
  • Shockwave C2 Aero Coronary IVL Catheter Next-generation coronary IVL catheter featuring enhanced deliverability through tortuous arteries, tapered tip design, hydrophilic coating for improved lesion crossing, and bidirectional repositioning capabilities. Available in the United States and Japan with rollout to Europe and Canada following.
  • Shockwave C2 Aero Fly Coronary IVL Catheter Coronary IVL catheter variant with fly design characteristics for enhanced procedural navigation during PCI in calcified coronary arteries.
  • Shockwave E8 Peripheral IVL Catheter Peripheral intravascular lithotripsy catheter designed for treatment of calcified peripheral artery disease, particularly in larger vessel diameters.
  • Shockwave Javelin Peripheral IVL Catheter Peripheral IVL catheter designed to treat difficult-to-cross calcified lesions in peripheral arteries, featuring an enhanced crossing profile for challenging peripheral anatomy.
  • Shockwave L6 Peripheral IVL Catheter Peripheral IVL catheter for treating calcified lesions in larger peripheral vessels.
  • Shockwave M5 Peripheral IVL Catheter Peripheral IVL catheter system for treating calcified peripheral artery disease.
  • Shockwave M5+ Peripheral IVL Catheter Enhanced version of the Shockwave M5 peripheral IVL catheter for treating calcified peripheral artery disease.
  • Shockwave S4 Peripheral IVL Catheter Peripheral IVL catheter for treating calcified lesions in smaller peripheral vessels.
  • Shockwave IVL Generator Generator system that powers Shockwave IVL catheters by delivering the electrical signals that produce ultrasonic acoustic pressure waves for calcium modification in coronary and peripheral arteries. Sold to hospitals as part of the IVL capital equipment footprint.
  • IVL Connector Cable Connecting cable that links the Shockwave IVL generator to the IVL catheter for energy delivery during procedures.
  • Shockwave Reducer (Rejuvenator System) Coronary sinus reduction device designed to treat refractory angina by reducing pressure in the coronary sinus. Investigational in the United States and Canada; available in select international geographies. For use by interventional cardiologists treating patients with chronic refractory angina.
  • Shockwave SkyRunner Carotid IVL System Investigational carotid intravascular lithotripsy system designed to treat calcified carotid arteries prior to stenting. Features rapid exchange capability and tailored sizing for carotid procedures. Currently in the SKYWARD IDE clinical program enrolling up to 320 subjects across 50 US sites.

Quantifiable outcome

  • 23% growth post-acquisition by J&J
  • +3 more outcomes

Companies that use Shockwave Medical

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Shockwave Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Shockwave Medical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Neovasc Inc.minorStrategic or Co-development Partner · 11 April 2023Shockwave Medical completed acquisition of Neovasc Inc. for approximately $100 million, including the Rejuvenator/Reducer System designed to treat refractory angina. The deal involved cash payment and potential deferred payments based on regulatory milestones, with Neovasc's shares being delisted from stock exchanges.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Shockwave Medical competitors and assessment

Company assessment

Broad incumbents

  • Boston Scientific: Major cardiovascular device incumbent; acquired Bolt Medical to enter the IVL category, directly challenging Shockwave's coronary and peripheral IVL franchises with a much larger commercial footprint.
  • Abbott Vascular: Large incumbent in coronary and peripheral intervention; acquired Cardiovascular Systems Inc. (CSI) to add orbital atherectomy for calcium modification, a directly competing calcium-treatment modality.
  • Medtronic: Global medtech incumbent with significant coronary and peripheral vascular device franchises; offers atherectomy, specialty balloons, and stents that overlap with Shockwave's procedural adjacency.

Regional players

  • AngioDynamics: Peripheral vascular and thrombectomy device company with overlapping peripheral intervention customer base, particularly in hospital and outpatient settings.

Direct peers

  • Penumbra: Specialist in peripheral vascular and thrombectomy interventions, with a growing footprint in treating complex PAD — overlapping with Shockwave's peripheral IVL and below-the-knee indications.
  • Silk Road Medical: Focused on carotid artery stenting (TCAR); directly comparable to Shockwave's emerging SkyRunner Carotid IVL program as the carotid indication expands.
  • Cardiovascular Systems Inc. (CSI / Abbott): Pioneer of orbital atherectomy for treating calcified coronary and peripheral lesions; now part of Abbott, it is the most direct mechanistic competitor to Shockwave IVL in calcium modification.

Emerging players

  • Recor Medical: Developer of ultrasound-based renal denervation therapy; shares Shockwave's use of acoustic energy in vascular applications, making it thematically comparable in modality, if not in indication.
  • Reflow Medical: Developer of specialty peripheral vascular devices including dedicated tools for calcified lesions; a smaller, emerging competitor with overlapping peripheral IVL-adjacent use cases.
  • LimFlow SA: Focused on below-the-knee and chronic limb-threatening ischemia interventions, directly adjacent to Shockwave's DISRUPT BTK clinical program and peripheral IVL use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Shockwave Medical social profiles

Digital presence

Shockwave Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Shockwave Medical leadership team

Management profile

Number of profiles

Profiles13 records

Shockwave Medical subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Shockwave Medical funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Shockwave Medical M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shockwave Medical

What does Shockwave Medical do?

Shockwave Medical develops, manufactures, and commercializes Intravascular Lithotripsy (IVL) devices — including coronary and peripheral IVL catheters, an IVL generator, connector cable, and investigational Reducer and SkyRunner systems — that use ultrasonic acoustic pressure waves to safely modify calcified plaque in cardiovascular arteries. These products are sold to hospitals, cardiac catheterization labs, and interventional specialists for the treatment of severely calcified coronary and peripheral artery disease, as well as refractory angina (under investigation in the US).

Is Shockwave Medical a public or private company?

Shockwave Medical is a private company. It is classified as corporate owned and is currently operating.

When was Shockwave Medical founded?

Shockwave Medical was founded in 2004. It employs 1,001 to 5,000 people.

Where is Shockwave Medical based?

Shockwave Medical is headquartered in Fremont, United States, in the North America region.

How does Shockwave Medical make money?

One revenue line is on record: medical Device Sales.

Who are Shockwave Medical's main competitors?

Broad incumbents on record are Boston Scientific, Abbott Vascular and Medtronic. AngioDynamics is listed as a regional player. Direct peers are Penumbra, Silk Road Medical and Cardiovascular Systems Inc. (CSI / Abbott). Emerging players are Recor Medical, Reflow Medical and LimFlow SA.

Does Shockwave Medical have an API?

No public API is recorded for Shockwave Medical.

What industry is Shockwave Medical in?

Shockwave Medical's product category is Intravascular Lithotripsy (IVL) Cardiovascular Devices. Its primary akta.pro industry code is HLAKABAB, Interventional Cardiology (PCI/Structural Heart), with a secondary code of HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarThree Life-Saving Medical Technologies Named Finalists for the Second Annual Thomas J. Fogarty Innovation PrizeThree medical technologies—frameless image-guided radiosurgery, JADA postpartum hemorrhage management, and shockwave intravascular lithotripsy—were named finalists for the second annual Thomas J. Fogarty Innovation Prize. The winner will receive a $100,000 cash prize and be announced at a San Diego gala on October 30.The Motley FoolI Think Johnson & Johnson Is the Best Dividend Stock to Buy Right NowThe author argues Johnson & Johnson is the best dividend stock to buy, citing its 64-year consecutive dividend increase and a 3.1% raise to $1.34 per quarter in April 2026. The company's annual dividend is about $5.36 with a yield near 2%, and it raised its 2026 sales guidance to $101.1 billion.Medical Device NetworkJ&J starts SKYWARD study of carotid IVL systemJohnson & Johnson has initiated enrollment in the SKYWARD IDE clinical programme to evaluate the Shockwave SkyRunner Carotid intravascular lithotripsy system, designed to treat calcified carotid arteries before stenting, with the first participant treated at McLaren Bay Region Hospital in Michigan. The programme comprises two prospective, multi-centre, single-arm studies enrolling up to 320 subjects across as many as 50 US sites, focusing on both transcarotid and transfemoral approaches. The investigational device, developed by J&J unit Shockwave Medical, features rapid exchange capability and tailored sizing for carotid procedures, aiming to generate evidence for expanding treatment options for patients with calcific carotid disease.Simply Wall St3 US Defensive Stocks With Strong Margins And Essential Healthcare DemandSimply Wall St published an analysis identifying three U.S. healthcare stocks as defensive investment options amid concerns over Federal Reserve independence and market volatility: Shockwave Medical (medical devices, $12.6B market cap), Change Healthcare (healthcare IT and payments infrastructure, $9.0B market cap), and Molina Healthcare (managed care plans, $10.2B market cap). The article highlights the companies' fundamentals, revenue breakdowns, margin profiles, and associated risks including high valuations, profitability challenges, and funding considerations. The piece serves as promotional content for Simply Wall St's screening tools while offering general investment commentary on defensive sector positioning.Medical Device NetworkHow Shockwave Medical plans to keep rivals at bay in burgeoning IVL sectorShockwave Medical, the first entrant in the intravascular lithotripsy (IVL) market which was acquired by Johnson & Johnson for $13.1bn in June 2024, outlined its strategy to maintain market leadership as major medtech competitors including Boston Scientific, Stryker, and Abbott enter the space. The company cited its first-to-market advantage, continuous annual device innovation, over 600 peer-reviewed publications covering 25,000-plus patients, and established reimbursement pathways as key differentiators. The IVL market, projected to exceed $2bn by 2034, is seeing increased competitive activity with Boston subsidiary Bolt Medical and Elixir Medical as the only other companies with approved IVL products alongside Shockwave.JaccExtensive Retrograde Dissection After Intravascular Lithotripsy Balloon Rupture: The Path of Least ResistanceAn 82-year-old woman underwent a percutaneous coronary intervention using intravascular lithotripsy, during which the Shockwave Medical balloon ruptured and subsequent contrast injection for imaging triggered an extensive retrograde coronary dissection. The medical team managed the complication by deploying a drug-eluting stent from the left anterior descending artery to the left main coronary artery, while conservative management was chosen for the dissection extending into the left circumflex artery. This case highlights that eccentric calcification can cause IVL balloon rupture even without severe tortuosity and warns against contrast-heavy imaging immediately following such ruptures.BioWorldAs IVL technologies advance, Shockwave looks to defend its leadShockwave Medical said its latest coronary IVL catheter, the C2 Aero, and other pipeline projects will help it maintain leadership in calcium modification. The company stated this as IVL market competition intensifies.MedicaldesignandoutsourcingThe new J&J Shockwave C2 Aero IVL device is faster and more flexibleJ&J's Shockwave C2 Aero IVL catheter, approved by the FDA in June 2025 and launched in the US and Japan in May 2026, features a redesigned shaft, flexible balloon, and tapered tip for improved deliverability and repositioning. It cuts post-pulsing pause time by 50%, reducing treatment time by 24%, and can be re-inserted up to three times.Medical Device NetworkBoston Scientific’s coronary IVL catheter hits primary endpoints in trialBoston Scientific's Seismiq 4CE coronary IVL catheter met primary endpoints in the FRACTURE trial, with 93.3% freedom from major adverse cardiac events and 93.7% procedural success. The results will support an FDA regulatory filing, and patients will be followed for two years.Clinical Trials ArenaBoston Scientific’s coronary IVL catheter hits primary endpoints in trialBoston Scientific's FRACTURE trial of its Seismiq 4CE coronary IVL catheter met primary endpoints, with 93.3% freedom from major adverse cardiac events at 30 days and 93.7% procedural success. The results will support an FDA regulatory filing for the device.